TokenPost·
FDA Requires GLP-1 Drug Labels to Disclose Potential NAION Risk
The Nov. 9, 2026, requirement covers medicines used for diabetes, weight loss and other approved purposes.
More news
- TokenPostDOJ Expected to Issue Opinion on Union Pacific Deal by Dec. 3
- TokenPostAmerican Petroleum Institute Estimate Puts Cushing Crude Stocks 5.1 Million Barrels Higher
- TokenPostMotorcar Parts of America Cites Approximately $60 Million in New Customer Business Awards
- TokenPostWarby Parker Shares Reach a 52-Week High After Earnings Results
- TokenPostVield Opens Bitcoin-Backed Lending Platform to Financial Firms
- NewsBTCStrategy Adds 1,036 BTC While Repurchasing $188M of STRC Preferred Shares